Assessment of the humoral immunity induced by Sputnik V Covid-19 vaccine (GAM-COVID-VAC) in healthcare workers

Vaccination for COVID-19 in healthcare workers (HCW) is essential to protect one of the populations most exposed to this disease. However, data on the humoral response rate to the vaccine and the factors associated with it in this population are limited. Therefore, we aimed to evaluate the antibody...

Full description

Saved in:
Bibliographic Details
Published in:Vacunas (Barcelona. Internet. English ed.) 2022-08, Vol.23, p.S14-S21
Main Authors: Cordova, Ezequiel, Lespada, M. Ines, Cecchini, Diego, Nieto, Fabiola, Palonski, Susana, Badran, Mariana, Bernasconi, Silvina, Bacelar, Brenda, Morganti, Laura, Garibaldi, Franco, Bermejo, Veronica, Aguirre, Viviana, Badia, Marcela, Rodriguez, Claudia G.
Format: Article
Language:English
Subjects:
COVID-19
healthcare workers
Original
Pandemia
pandemic
Personal de salud
SARS-CoV-2
Sputnik V vaccine
vaccines
Vacuna Sputnik V
Vacunas
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccination for COVID-19 in healthcare workers (HCW) is essential to protect one of the populations most exposed to this disease. However, data on the humoral response rate to the vaccine and the factors associated with it in this population are limited. Therefore, we aimed to evaluate the antibody response against SARS-CoV-2 in HCWs with complete Sputnik V vaccine scheme and factors associated with an increased antibody response. Prospective study to evaluate the anti-SARS-CoV-2 humoral response in HCWs vaccinated with two doses of the Sputnik V vaccine (April-July 2021). The assessment of anti-Spike IgG antibodies in plasma was performed using the COVIDAR IgG enzyme-linked immunosorbent assay. A logistic regression was performed to identify independent factors associated with a positive IgG serology test and an elevated antibody response. A total of 630 HCWs were enrolled. Median age (IQR): 47 years (35-56). Female sex: 462 (73.33%). Previous COVID-19: 158 (25%). The median interval time between vaccine doses was 3 (3-4) weeks. Positive serology was observed in 607 (96.35%) HCWs. In the multivariate analysis, a history of systemic reactogenicity was identified as an independent variable associated with a positive serology; and history of systemic reactogenicity, COVID-19, interval between doses ≥4 weeks and time to serology
ISSN:2445-1460
2445-1460
DOI:10.1016/j.vacune.2022.05.003